Prescient Therapeutics (ASX: PTX) — Perfil da empresa, notícias e dados financeiros
Prescient Therapeutics is a clinical-stage biotechnology company developing gene editing and T-cell therapies for cancer.
Prescient Therapeutics
Prescient Therapeutics is a clinical-stage oncology company focused on developing personalized medicines and targeted cell therapies for cancer treatment. Headquartered in Melbourne, Australia, the company develops targeted small molecule inhibitors and modular cell therapy platforms designed to address difficult-to-treat cancers. Its lead clinical candidates target essential cellular survival pathways in hematological malignancies such as T-cell lymphomas and acute myeloid leukemia, as well as solid tumors including breast and ovarian cancers. The company collaborates with international research institutions to conduct clinical trials, advance drug candidate pipelines, and optimize autologous and allogeneic cell manufacturing capabilities for oncological applications.
Resumo
Operações
Produtos e/ou serviços de Prescient Therapeutics
- Targeted Small Molecule Therapies: Clinical-stage small molecule inhibitors targeting specific cancer signaling pathways, including a targeted prenylation inhibitor undergoing clinical evaluation for peripheral T-cell lymphoma and cutaneous T-cell lymphoma treatment across multiple healthcare research centers.
- Controllable Cellular Therapies: Universal chimeric antigen receptor cell therapy platforms engineered to provide modular control over target antigen binding and dose-dependent immune response modulation for scalable treatments in hematological malignancies and solid tumors.
- Protein Kinase Inhibitors: Small molecule Akt kinase inhibitors designed to block cell survival pathways in cancer cells, evaluated in clinical trials for acute myeloid leukemia, HER2-negative breast cancer, and recurrent ovarian cancer indications across clinical centers.
- Targeted Cell Therapy Enhancers: Specialized cell processing and manufacturing technologies engineered to enhance immune cell persistence, expanding functional capability and target binding affinity during patient-specific autologous and allogeneic cellular immunotherapy manufacturing processes.
- Hematological Malignancy Treatments: Specialized drug development operations conducting phase one and phase two clinical trials focused on relapsed or refractory T-cell lymphomas and blood cancers across partnering medical research sites in Australia and North America.
- Solid Tumor Therapeutics: Research and development programs evaluating targeted small molecule drug combinations and modular cellular immunotherapies engineered to infiltrate dense tumor microenvironments across difficult-to-treat solid tumor indications in early-stage trials.
equipe executiva do Prescient Therapeutics
- James McDonnellChief Executive Officer
- Melanie Jaye LeydinCFO & Company Secretary
- Rebecca TunstallChief Operating Officer
- Rosalind WilsonChief Medical Officer
Últimas notícias sobre a Prescient Therapeutics
Comunicados recentes
O que a Prescient Therapeutics (PTX) comunicou ao mercado, do mais recente para o mais antigo.
- September 2026 Quarterly Update and Appendix 4CFato relevante
- Change of Director's Interest Notice
- Change of Director's Interest Notice
- Change of Director's Interest Notice
Principais indicadores financeiros
Resultados divulgados pela Prescient Therapeutics, em AUD.
- Cap. de mercado
- 62,9 mi
- Receita (TTM)
- 3,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.0
- Dividend yield
- —
- Margem de lucro
- -202.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -10,6 mi | -7 mi | |
| 4,4 mi | -7,5 mi | -7,3 mi | |
| 3,7 mi | -7,2 mi | -8,2 mi | |
| 2,4 mi | -9,9 mi | -7 mi |